| abstract |
This invention relates to nucleic acids and polypeptide sequences, which code for an interferon-beta-2 ('IFN-β2'). A pharmaceutical composition, which comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a human IFN-β2 polypeptide, biologically-active fragment thereof, or biologically-active derivative thereof, is useful in treating multiple sclerosis in humans. |